Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Free Cash Flow (2020 - 2022)

Atea Pharmaceuticals has reported Free Cash Flow over the past 3 years, most recently at -$21.5 million for Q4 2022.

  • Quarterly results put Free Cash Flow at -$21.5 million for Q4 2022, up 71.43% from a year ago — trailing twelve months through Dec 2022 was -$122.9 million (down 41.28% YoY), and the annual figure for FY2025 was -$132.0 million, up 2.56%.
  • Free Cash Flow for Q4 2022 was -$21.5 million at Atea Pharmaceuticals, down from -$21.3 million in the prior quarter.
  • Over the last five years, Free Cash Flow for AVIR hit a ceiling of $318.5 million in Q4 2020 and a floor of -$75.4 million in Q4 2021.
  • Median Free Cash Flow over the past 3 years was -$17.1 million (2021), compared with a mean of $7.2 million.
  • Peak annual rise in Free Cash Flow hit 338.03% in 2021, while the deepest fall reached 273.49% in 2021.
  • Atea Pharmaceuticals' Free Cash Flow stood at $318.5 million in 2020, then tumbled by 123.68% to -$75.4 million in 2021, then skyrocketed by 71.43% to -$21.5 million in 2022.
  • The last three reported values for Free Cash Flow were -$21.5 million (Q4 2022), -$21.3 million (Q3 2022), and -$20.4 million (Q2 2022) per Business Quant data.